Memphasys is an ASX-listed reproductive biotechnology company driven by market needs to provide reproduction and fertility solutions for humans and animals alike
Memphasys is an ASX-listed reproductive biotechnology company driven by market needs to provide reproduction and fertility solutions for humans and animals alike
| Rank | Company | 1 Yr | 5 Yr |
|---|---|---|---|
| 1436th | VEEM | -38.95% | -10.87% |
| 1437th | Enero Group | -39.32% | -29.08% |
| 1438th | Memphasys | -39.47% | -37.85% |
| 1439th | Synlait Milk | -39.69% | -33.26% |
| 1440th | Lifestyle Communities | -39.97% | -18.85% |
|
NEW ROLE: David Ali, Acting CEO, Executive Director | 01 Aug 2024 |
|
NEW ROLE: Robert Cooke, Non-Executive Chairman, Non-Executive Director | 01 Aug 2024 |
| NEW ROLE: Michael Atkins, Non-Executive Director | 01 Aug 2024 | |
|
NEW ROLE: David Ali, | 30 Oct 2023 |
|
NEW ROLE: Hassan Bakos, | 30 Oct 2023 |
|
NEWS: Tagged in Memphasys to reinvest tax refund in the next generation | 25 Oct 2023 |
|
NEWS: Tagged in Memphasys brings Indian baby dreams alive with Felix | 15 Sep 2023 |
|
NEWS: Tagged in Memphasys franks Japan deal with first Felix order | 14 Aug 2023 |
|
NEWS: Tagged in Memphasys inks deal with global IVF provider Vitrolife | 07 Aug 2023 |
Access to our data for Memphasys is only available to paid subscribers with Data & Insights access.
Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.
Memphasys is included in 1 list - Public Companies - non WA.
For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.